Readystate Asset Management LP Has $1.04 Million Stake in Enfusion, Inc. (NYSE:ENFN)

Readystate Asset Management LP grew its stake in Enfusion, Inc. (NYSE:ENFN) by 173.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 109,243 shares of the company’s stock after purchasing an additional 69,328 shares during the period. Readystate Asset Management LP owned about 0.09% of Enfusion worth $1,037,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. RiverPark Advisors LLC acquired a new position in shares of Enfusion in the 2nd quarter valued at $68,000. Arizona State Retirement System acquired a new position in shares of Enfusion in the 2nd quarter valued at $86,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Enfusion in the 1st quarter valued at $102,000. Harbor Capital Advisors Inc. raised its stake in shares of Enfusion by 12.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after buying an additional 1,315 shares in the last quarter. Finally, Belvedere Trading LLC acquired a new position in shares of Enfusion in the 3rd quarter valued at $114,000. 81.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, COO Neal Pawar sold 21,801 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $10.03, for a total value of $218,664.03. Following the sale, the chief operating officer now owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. The trade was a 1.87 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 36.44% of the company’s stock.

Enfusion Stock Performance

Shares of ENFN stock opened at $10.11 on Thursday. Enfusion, Inc. has a 52-week low of $7.52 and a 52-week high of $10.40. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of 252.81, a P/E/G ratio of 3.79 and a beta of 0.97. The firm has a fifty day moving average of $9.36 and a 200-day moving average of $8.90.

Enfusion Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.